# Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets

> **NCT03090139** · — · COMPLETED · sponsor: **Takeda** · enrollment: 1731 (actual)

## Conditions studied

- Colitis, Ulcerative
- Crohn Disease
- Inflammatory Bowel Diseases

## Interventions

- **DRUG:** Anti-TNF Therapy

## Key facts

- **NCT ID:** NCT03090139
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-28
- **Primary completion:** 2018-06-13
- **Final completion:** 2018-06-13
- **Target enrollment:** 1731 (ACTUAL)
- **Last updated:** 2018-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03090139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03090139, "Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT03090139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*